Corvus Pharmaceuticals
CRVS· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +43.9% in FY2025
Richard A. Miller, M.D. is the CEO of Corvus Pharmaceuticals and was paid $7.0M in FY2025 (Dec), up 129%.
Pay$100 in the stock at the end of FY21 → $320
Executives3
See all- 1Richard A. Miller, M.D.President and Chief Executive OfficerFY2025
- 2Leiv LeaChief Financial OfficerFY2025
- 3William B. Jones, Ph.D.Senior Vice President, Pharmaceutical DevelopmentFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCorvus Pharmaceuticals paid its 3 named executives $13.4M in total in FY2025 (Dec). CEO Richard A. Miller, M.D. was paid $7.0M of that.
| Name | |||
|---|---|---|---|
| Richard A. Miller, M.D.President and Chief Executive Officer | |||
| Leiv LeaChief Financial Officer | |||
| William B. Jones, Ph.D.Senior Vice President, Pharmaceutical Development |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Corvus Pharmaceuticals. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- Peter ThompsonDirector · 9 yr on the boardIndependentCompensation (Chair)—Paid as an executive
- Scott W. MorrisonDirector · 8 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Linda S. Grais, M.D. J.D.Director · 4 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2023).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 24, 2026 | FY2025 |
| Annual report | 10-K | Mar 12, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Mar 25, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 19, 2024 | FY2023 |
